John Chee Kuen Hui PhD
President and Chief Executive Officer, and Director of Vasomedical, Inc.

John CK Hui has over 30 years of experience in the technology and medical fields, including more than 13 years at Vasomedical, Inc. (NASDAQ-VASO), a world leader in the design and development of enhanced external counterpulsation (EECP) systems.
Prior to Vasomedical he was President and CEO of Vasogenics, a company that first introduced EECP technology, a noninvasive treatment of cardiovascular disease, to the commercial world.

John Hui has published more than 60 clinical and scientific papers. He also holds 6 patents. John also remains actively involved in the education field. He is an assistant professor with the Department of Medicine (Cardiology Division) and the Department of Surgery at the State University of NY at Stony Brook, NY. John is also a research scientist in Brookhaven National Laboratory.
 
After graduating with a BA in physics from International Christian University Tokyo, Japan in 1969 spent a year at the University of California, Berkeley before moving to the State University of New York, Stony Brook where he obtained his Masters degree in 1972 and his doctorate in 1975.  During his graduate research period in the thermodynamics of solids, Dr. Hui studied at the Cavendish Laboratories at Cambridge University in the United Kingdom.

2008 - Aging, Prevention and Wellness-endothelial & vascular health

Title: Endothelial Dysfunction and Vascular Aging
Presenter: John CK Hui

Vascular aging is a progressive process starting with increased arterial stiffness, progressing to higher systolic pressure, increased left ventricular workload and oxygen demand, leading to left ventricular hypertrophy and finally, heart failure. Arteriosclerosis can be considered as accelerated vascular aging initiated by endothelial dysfunction. Increasing blood flow can attenuate the progressive deterioration of endothelial function associated with aging as demonstrated by the beneficial effect of regular exercise. A circulation assist device known as Enhanced External Counterpulsation (EECP) has also been shown to improve endothelial function, reduce arterial stiffness, lower vasoconstrictive agents such as endothelin and angiotensin II, as well as inflammatory cytokines and adhesion molecules, and increase circulating endothelial progenitor cells. EECP therapy consists of applying up to 260 mm Hg of external compressive pressure in synchronization with the cardiac cycle with three sets of cuffs wrapped around the lower extremities during diastole to produce a retrograde blood flow to increase coronary perfusion. The pressures in the cuffs are released during systole to produce systolic unloading, and increase cardiac output. EECP therapy is currently used to treat refractory angina pectoris and heart failure patients. Long-term effects of EECP therapy on improving the quality of life and diminish the progression of cardiovascular disease as we age remains to be examined